Description

ATOSTRATT 40 CAP is a specialized medication formulated with Atomoxetine Hydrochloride 40 mg, designed for the management of Attention Deficit Hyperactivity Disorder (ADHD). As a non-stimulant, Atomoxetine offers a reliable and well-tolerated alternative to traditional stimulant-based ADHD therapies like methylphenidate or amphetamines.

Atomoxetine acts by selectively inhibiting the presynaptic norepinephrine transporter, increasing norepinephrine levels in the prefrontal cortex. This enhanced neurotransmitter activity improves attention span, decreases hyperactivity, and reduces impulsiveness—helping individuals manage ADHD symptoms effectively.

• ADHD in children (6 years and older)

• ADHD in adolescents and adults

• Can be prescribed for patients who cannot tolerate stimulant medications

• Off-label use in conditions like depression with executive dysfunction (physician-directed)

Atomoxetine increases norepinephrine levels by blocking its reuptake, thereby improving communication between brain cells in regions associated with focus, self-regulation, and behavior control. Unlike stimulants, Atomoxetine is not addictive and has a gradual onset of action.

• Non-stimulant ADHD medication

• Long-acting, once-daily dosing

• No known risk of abuse or dependence

• Well-tolerated for long-term use

• Can be used in individuals with substance abuse history or cardiac risks

• Typically initiated at 40 mg per day

• Dose may be adjusted to 80–100 mg daily based on patient response

• Administered once or twice daily with or without food

• Therapeutic effects may take 1–2 weeks to become noticeable

• Dry mouth, decreased appetite, nausea

• Fatigue, dizziness, mood swings

• Sleep disturbances or sexual side effects (in adults)

• Rare: Liver enzyme elevation, suicidal ideation (requires close monitoring)

• Regular monitoring in pediatric and adolescent patients for growth, mood changes, and cardiovascular status

• Liver function tests recommended in prolonged therapy

• Contraindicated in patients with narrow-angle glaucoma or severe cardiovascular disorders

• Use with caution in patients taking MAO inhibitors (contraindicated within 14 days)

ATOSTRATT 40 CAP is proudly manufactured and globally distributed by Bluepill Express, a leading Indian pharmaceutical company known for its dedication to third-party manufacturing, private labeling, and international exports.

Bluepill Express operates under the highest standards of WHO-GMP, ISO certification, and stringent regulatory compliance, ensuring the safe and consistent supply of quality pharmaceutical products to markets including:

• Asia and Southeast Asia

• Africa and the Middle East

• Latin America

• CIS Countries

• Europe, UK, and Australia

• Custom branding and contract manufacturing for Atomoxetine

• Flexible batch sizes with prompt delivery

• Export documentation support (COA, MSDS, COPP, FSC, etc.)

• Competitive pricing with bulk order capabilities